Skip Ribbon Commands
Skip to main content

News

 

 

TERUMO CARDIOVASCULAR CELEBRATES 40TH ANNIVERSARY OF CAPIOX® OXYGENATORShttps://www.terumo-europe.com/en-emea/news/terumo-cardiovascular-celebrates-40th-anniversary-of-capiox®-oxygenatorsTERUMO CARDIOVASCULAR CELEBRATES 40TH ANNIVERSARY OF CAPIOX® OXYGENATORSANN ARBOR, MICH8/30/2022 10:00:00 PM<p>​Terumo Cardiovascular, a global leader in cardiovascular surgery technologies, is celebrating the 40th anniversary of its industry-leading Capiox brand of oxygenators. <br></p>
Terumo Announces Regulatory Approval of Drug-Device Combination Product Co-Developed with Kyowa Kirinhttps://www.terumo-europe.com/en-emea/news/terumo-announces-regulatory-approval-of-drug-device-combination-product-co-developed-with-kyowa-kirinTerumo Announces Regulatory Approval of Drug-Device Combination Product Co-Developed with Kyowa KirinTOKYO, JAPAN8/1/2022 10:00:00 PMExpected to Reduce the Burden on Patients Receiving Chemotherapy<br>
Terumo Unveils “Terumo’s Purpose” to Enhance Joint Value Creation with Diverse Stakeholdershttps://www.terumo-europe.com/en-emea/news/terumo-unveils-terumo’s-purpose-to-enhance-joint-value-creation-with-diverse-stakeholdersTerumo Unveils “Terumo’s Purpose” to Enhance Joint Value Creation with Diverse StakeholdersTOKYO, JAPAN 7/7/2022 10:00:00 PM<p>Terumo Corporation (TSE: 4543) today unveils "Terumo's Purpose" to promote joint creation of value with diverse stakeholders. To communicate the message, Terumo has released a new corporate branding video and key visual.<br></p>
First results of DISCO RADIAL, a Terumo sponsored studyhttps://www.terumo-europe.com/en-emea/news/first-results-of-disco-radial-a-terumo-sponsored-studyFirst results of DISCO RADIAL, a Terumo sponsored studyLEUVEN, BELGIUM6/14/2022 10:00:00 PMLate Breaking Trial presentation at EuroPCR 2022 with simultaneous publication in the Journal of the American College of Cardiology (JACC)<p><br></p>
Holmium-166 SIRT demonstrates safety and efficacy in the treatment of Hepatocellular carcinoma (HCC)https://www.terumo-europe.com/en-emea/news/holmium-166-sirt-demonstrates-safety-and-efficacy-in-the-treatment-of-hepatocellular-carcinoma-(hcc)Holmium-166 SIRT demonstrates safety and efficacy in the treatment of Hepatocellular carcinoma (HCC)LEUVEN, BELGIUM6/13/2022 10:00:00 PM<p>​Terumo Europe N.V. is proud to share the latest clinical news regarding Holmium-166 (QuiremSpheres<sup>TM</sup> holmium-166 microspheres) Selective Internal Radiation Therapy (SIRT). On May 19, 2022, the UMC Utrecht published their latest results in the JNM 2022 from the HEPAR Primary study. The study evaluated the safety and efficacy of Holmium-166 SIRT in the treatment of HCC patients (BCLC stage B & C) without curative options. <br></p>